Flavin-containing monooxygenase 2 confers cardioprotection in ischemia models through its disulfide bond catalytic

Qingnian Liu1,2, Jiniu Huang1,2, Hao Ding1,2

  • 1Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Insights

Flavin-containing monooxygenase 2 (FMO2) protects heart cells from death after myocardial infarction (MI). Overexpressing FMO2 reduces cardiac dysfunction, highlighting its therapeutic potential for ischemic heart disease.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Oxidative Protein Folding

Background:

  • Myocardial infarction (MI) causes significant cardiomyocyte (CM) death and cardiac dysfunction, necessitating novel cardioprotective therapies.
  • Current therapeutic strategies for ischemic heart disease are limited in their ability to prevent CM death and restore cardiac function.

Purpose of the Study:

  • To investigate the role of flavin-containing monooxygenase 2 (FMO2) in cardiomyocyte survival and cardiac function following ischemic injury.
  • To elucidate the underlying molecular mechanisms by which FMO2 exerts cardioprotection.

Main Methods:

  • Utilized ex vivo and in vivo models of ischemic injury, including genetic deletion and overexpression of FMO2 in cardiomyocytes.
  • Investigated the impact of FMO2 on endoplasmic reticulum (ER) stress pathways, apoptotic proteins (caspase 12, CHOP), and oxidative protein folding.
  • Employed a GVSG-mutated FMO2 to assess the role of its chaperone activity in protection.
  • Validated findings using human induced pluripotent stem cell-derived CMs.

Main Results:

  • FMO2 levels were upregulated in cardiomyocytes following ischemic injury.
  • Genetic deletion of FMO2 exacerbated CM death and cardiac dysfunction, while FMO2 overexpression conferred protection.
  • FMO2 inhibited ER stress-induced apoptosis by downregulating the unfolded protein response pathway.
  • FMO2 functions as a chaperone, catalyzing disulfide bond formation in unfolded proteins via its GVSG motif, which is crucial for its protective function.
  • FMO2 demonstrated protective effects in human iPSC-derived CMs.

Conclusions:

  • FMO2 plays a critical protective role in cardiomyocytes against ischemic injury.
  • FMO2 acts as a chaperone, facilitating oxidative protein folding and mitigating ER stress-induced apoptosis.
  • FMO2 represents a promising therapeutic target for treating ischemic heart disease and improving cardiac function post-MI.